$1.41
2.76% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

PDS Biotechnology Corp. Stock price

$1.41
-0.02 1.40% 1M
-0.30 17.54% 6M
-0.22 13.50% YTD
-1.60 53.16% 1Y
-2.52 64.12% 3Y
-1.19 45.77% 5Y
-257.39 99.46% 10Y
-257.39 99.46% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.04 2.76%
ISIN
US70465T1079
Symbol
PDSB
Sector
Industry

Key metrics

Basic
Market capitalization
$64.5m
Enterprise Value
$43.4m
Net debt
$-21.0m
Cash
$40.0m
Shares outstanding
45.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.87
Financial Health
Equity Ratio
41.90%
Return on Equity
-197.90%
ROCE
-122.84%
ROIC
-
Debt/Equity
0.85
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-35.3m | $-43.8m
EBIT
$-35.3m
Net Income
$-35.5m | $-38.5m
Free Cash Flow
$-34.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
19.22% | -20.68%
EBIT
19.20%
Net Income
19.10% | -2.31%
Free Cash Flow
-12.31%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.87
FCF per Share
$-0.75
Short interest
4.49%
Employees
24.00
Rev per Employee
$0.00
Show more

Is PDS Biotechnology Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

PDS Biotechnology Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a PDS Biotechnology Corp. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a PDS Biotechnology Corp. forecast:

Buy
89%
Hold
11%

Financial data from PDS Biotechnology Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
10% 10%
-
- Research and Development Expense 22 22
24% 24%
-
-35 -35
19% 19%
-
- Depreciation and Amortization 0.06 0.06
0% 0%
-
EBIT (Operating Income) EBIT -35 -35
19% 19%
-
Net Profit -36 -36
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about PDS Biotechnology Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PDS Biotechnology Corp. Stock News

Neutral
GlobeNewsWire
19 days ago
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe
Neutral
GlobeNewsWire
26 days ago
PDS Biotech announced the publication of three Versamune® HPV abstracts that were presented during the Head and Neck Cancer Poster Session at ASCO 2025.
More PDS Biotechnology Corp. News

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Head office United States
CEO Frank Bedu-Addo
Employees 24
Founded 2005
Website www.pdsbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today